Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02483247 · ClinicalTrials.gov registry record · Phase 1
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 165
- Enrollment target
NCT02483247: Completed Phase 1 study, sponsored by Sumitomo Pharma America.
NCT02483247 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 165 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (175% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02483247, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 165 participants
- Enrollment target
Study Summary
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the study is to determine the safety, tolerability, and RP2D of BBI503 in combination with each of the selected anti-cancer agents.
Interventions
- DRUG Pembrolizumab
- DRUG Capecitabine
- DRUG Doxorubicin
- DRUG Nivolumab
- DRUG BBI503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-05 |
| Phase | Phase 1 |
What the finished NCT02483247 record still lists
NCT02483247 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (175% higher).
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02483247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02483247 about?
NCT02483247 is a clinical study titled "A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer". This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the study is to determine the safety, tolerability, and RP2D of BBI503 in combination with each of the selected anti-c...
What is the current status of trial NCT02483247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2015-09. Estimated completion is 2019-05.
What interventions are being tested in trial NCT02483247?
The interventions under investigation include: Pembrolizumab (DRUG), Capecitabine (DRUG), Doxorubicin (DRUG), Nivolumab (DRUG), BBI503 (DRUG).
Who is sponsoring clinical trial NCT02483247?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02483247's enrollment target sits among peer trials
165 332nd of 2000 higher than 1,666 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia